Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-25T21:16:12.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed information about a phase 2 study involving zimberelimab and the addition of new drug names and identifiers related to lung cancer treatments.
    Difference
    20%
    Check dated 2025-04-18T14:45:59.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The page has been updated to reflect the latest version as v2.14.4, replacing the previous version v2.14.3. The phrasing regarding the last update has also changed from 'Estimated' to a definitive statement.
    Difference
    0.1%
    Check dated 2025-04-03T22:11:36.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 26, 2025, and version 2.14.2.
    Difference
    0.3%
    Check dated 2025-03-27T15:13:20.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The page has updated the number of study locations from 104 to 103 and changed the location from Patra, Greece to Guadalajara, Mexico.
    Difference
    1%
    Check dated 2025-03-06T02:53:22.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-19T15:50:38.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.